Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients - Université de Lorraine Access content directly
Journal Articles JACC: Heart Failure Year : 2019
No file

Dates and versions

hal-02510373 , version 1 (17-03-2020)

Identifiers

Cite

Patrick Rossignol, Joao Pedro Ferreira. Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients. JACC: Heart Failure, 2019, 7 (1), pp.33-35. ⟨10.1016/j.jchf.2018.11.016⟩. ⟨hal-02510373⟩
32 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More